A review of adherence to drug therapy in patients with overactive bladder

被引:112
作者
Basra, Ramandeep K. [1 ]
Wagg, Adrian [2 ]
Chapple, Christopher [3 ]
Cardozo, Linda [4 ]
Castro-Diaz, David [6 ]
Pons, Montserrat Espuna [7 ]
Kirby, Mike [5 ]
Milsom, Ian [8 ]
Vierhout, Mark [9 ]
Van Kerrebroeck, Philip [10 ]
Kelleher, Con [1 ]
机构
[1] Guys St Thomas NHS Fdn Trust, Sheffield, S Yorkshire, England
[2] Univ Coll London, Sheffield, S Yorkshire, England
[3] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
[4] Kings Coll Hosp London, London, England
[5] Univ Hertfordshire, Ctr Res Primary & Community Care, Hatfield AL10 9AB, Herts, England
[6] Univ Canarias, Tenerife, Spain
[7] Univ Barcelona, Barcelona, Spain
[8] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[9] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[10] Univ Hosp Maastricht, Maastricht, Netherlands
关键词
adherence; overactive bladder; pharmacotherapy;
D O I
10.1111/j.1464-410X.2008.07769.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Drug therapy for overactive bladder (DAB) is associated with improvements in symptoms and quality of life, but the short- and long-term adherence and persistence is suboptimal. In this review we outline methods of measuring, and factors affecting, adherence to pharmacatherapy in patients with CAB. Clinical practice suggests that adherence rates reported in clinical trials art much greater than in real practice. Factors affecting adherence include psychological and social variables that might alter patients' perception of the benefits of taking medication, and the effect of comorbidity and polypharmacy. Whilst there is some evidence that lack of efficacy and side-effects are contributory, these additional factors are also important.
引用
收藏
页码:774 / 779
页数:6
相关论文
共 25 条
[11]   Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence [J].
Dmochowski, RR ;
Davila, GW ;
Zinner, NR ;
Gittelman, MC ;
Saltzstein, DR ;
Lyttle, S ;
Sanders, SW .
JOURNAL OF UROLOGY, 2002, 168 (02) :580-586
[12]  
Dunbar-Jacob Jacqueline, 2003, J Cardiovasc Nurs, V18, P209
[13]   Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome [J].
Haab, F ;
Cardozo, L ;
Chapple, C ;
Ridder, AM .
EUROPEAN UROLOGY, 2005, 47 (03) :376-384
[14]   Persistence with antimuscarinic therapy in patients with overactive bladder [J].
Haab, F ;
Castro-Diaz, D .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (08) :931-937
[15]   Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study [J].
Haab, Francois ;
Corcos, Jacques ;
Siami, Paul ;
Glavind, Karin ;
Dwyer, Peter ;
Steel, Michael ;
Kawakami, Fernando ;
Lheritier, Karine ;
Steers, William D. .
BJU INTERNATIONAL, 2006, 98 (05) :1025-1032
[16]   Long-term management of overactive bladder with antimuscarinic agents [J].
Hampel, Christian .
EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (05) :432-437
[17]  
Haynes RB, 1996, LANCET, V348, P383
[18]   The overactive bladder in children:: a potential future indication for tolterodine [J].
Hjälmås, K ;
Hellström, AL ;
Mogren, K ;
Läckgren, G ;
Stenberg, A .
BJU INTERNATIONAL, 2001, 87 (06) :569-574
[19]   Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study [J].
Irwin, Debra E. ;
Milsom, Ian ;
Hunskaar, Steinar ;
Reilly, Kate ;
Kopp, Zoe ;
Herschorn, Sender ;
Coyne, Karin ;
Kelleher, Con ;
Hampel, Christian ;
Artibani, Walter ;
Abrams, Paul .
EUROPEAN UROLOGY, 2006, 50 (06) :1306-1315
[20]   A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance [J].
Kelleher, CJ ;
Cardozo, LD ;
Khullar, V ;
Salvatore, S .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1997, 104 (09) :988-993